Valsartan reduces arterial stiffness along with level of soluble ST2 independently of blood pressure changes

Abstract Introduction Arterial stiffness is one of end-organ damage signs in patients with arterial hypertension. Carotid femoral pulse wave velocity (cfPWV) a clinical measure and its values above 10 m/sec are associated increased cardiovascular risk. Soluble ST2 cytokine involved fibrotic processes. There paucity data on the association between sST2, stiffness, effect valsartan these parameters. Objectives The aim study was to assess level soluble over 12-month long treatment. Methods This randomized, blinded, placebo controlled single center study. 24-hour-long wash-out period from angiotensin converting enzyme inhibitors (ACEI) other than valsartan, receptor blockers ARB (previous use an exclusion criterion). Drugs ACEI were allowed follow-up control blood pressure. CfPWV assessed at baseline 12 months using applanation tonometry. measured lateral flow cassette-based immunofluorescent assay. We present for 28 (Plac) 60 (Vals). Results Patients both groups have had comparable peripheral central pressures. has risen Plac by 6.2% fallen Vals (P=0.01) months. 9.4% 43.3% (P=0.001) Conclusion Valsartan positive improvement stiffness. Decrease concentration may help explain alternative mechanism protective role valsartan. Funding Acknowledgement Type funding sources: Public Institution(s). Main source(s): Medical University Silesia